Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug–Drug Interaction Between Voriconazole and Flucloxacillin
Ex vivo experiments reported that the unbound voriconazole plasma concentration remained unchanged after adding flucloxacillin. The PBPK model describes the potential mechanism driving the drug-drug and drug-disease interaction of voriconazole and flucloxacillin, highlighting the large substantial influence of flucloxacillin on the PXR gene and the influence of infection on voriconazole plasma concentrations, and suggests a more limited effect on other triazoles.
Authors
- Maarten R. Seefat (ORCID: https://orcid.org/0000-0002-0824-0354)
- Medhat M. Said (ORCID: https://orcid.org/0000-0001-7954-6580)
- N. Harry Hendrikse (ORCID: https://orcid.org/0000-0001-8072-5391)
- H. Abdullah-Koolmees (ORCID: https://orcid.org/0000-0003-3789-2383)
- Julia F van den Nieuwendijk
- David C. de Leeuw (ORCID: https://orcid.org/0000-0003-4591-8467)
- Linda G. W. Franken (ORCID: https://orcid.org/0000-0001-6436-9825)
- Simone M K Ten Hoope
- E Swart
- Imke H. Bartelink (ORCID: https://orcid.org/0000-0001-9602-3407)
Institutions
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Cancer Center Amsterdam (NL)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- European Journal of Drug Metabolism and Pharmacokinetics
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1007/s13318-024-00916-1
- Citations
- 3
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 1.17